| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOO |
| Uniprot No | Q9BUR5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198aa |
| 氨基酸序列 | MFKVIQRSVGPASLSLLTFKVYAAPKKDSPPKNSVKVDELSLYSVPEGQSKYVEEARSQLEESISQLRHYCEPYTTWCQETYSQTKPKMQSLVQWGLDSYDYLQNAPPGFFPRLGVIGFAGLIGLLLARGSKIKKLVYPPGFMGLAASLYYPQQAIVFAQVSGERLYDWGLRGYIVIEDLWKENFQKPGNVKNSPGTK |
| 预测分子量 | 22,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOO重组蛋白的模拟参考文献示例(注：部分内容基于领域研究趋势整合，非真实文献)：
---
1. **文献名称**: *"Apolipoprotein O regulates mitochondrial membrane stability and cardiomyocyte function"*
**作者**: Zhang L, et al.
**摘要**: 本研究探讨了APOO重组蛋白在线粒体膜稳定性中的作用，发现其通过调节脂质组成影响心肌细胞能量代谢。敲低APOO导致小鼠模型中心肌功能异常，提示其在心血管疾病中的潜在病理机制。
2. **文献名称**: *"Recombinant APOO expression in HEK293 cells: purification and functional characterization in cholesterol transport"*
**作者**: Kim S, Patel RD.
**摘要**: 报道了利用HEK293细胞系统高效表达APOO重组蛋白的方法，并证实其与HDL颗粒结合后促进胆固醇逆向转运，为动脉粥样硬化治疗提供了新靶点。
3. **文献名称**: *"APOO genetic variants and association with Alzheimer’s disease neuropathology"*
**作者**: García E, et al.
**摘要**: 通过人群队列分析，发现APOO基因多态性与脑脊液中β-淀粉样蛋白沉积水平相关，提示APOO可能通过脂代谢途径参与阿尔茨海默病的神经退行性过程。
4. **文献名称**: *"Apolipoprotein O modulates insulin sensitivity via adipose tissue inflammation"*
**作者**: Wang Y, et al.
**摘要**: 实验表明，APOO重组蛋白过表达加剧脂肪组织炎症反应和胰岛素抵抗，而抑制剂可改善小鼠代谢综合征表型，为糖尿病干预提供了新思路。
---
**注**：以上文献为模拟示例，实际研究中建议通过PubMed或Web of Science以“Apolipoprotein O”或“APOO recombinant protein”为关键词检索最新文献。
APOO (Apolipoprotein O), also known as FAM121B, is a mitochondrial membrane-associated protein encoded by the APOO gene in humans. Initially identified in 2008. APOO belongs to the apolipoprotein family but exhibits distinct structural and functional characteristics. It is ubiquitously expressed, with higher levels observed in tissues rich in mitochondria, such as the heart, liver, and skeletal muscle. APOO is characterized by a single transmembrane domain and a conserved C-terminal region, suggesting roles in lipid metabolism and cellular homeostasis.
Studies have linked APOO to mitochondrial function, particularly in cholesterol metabolism and apoptosis regulation. It interacts with proteins like MIC26/MIC60 in the mitochondrial contact site and cristae organizing system (MICOS), influencing cristae morphology and mitochondrial membrane stability. Dysregulation of APOO has been implicated in metabolic disorders, including cardiovascular diseases and non-alcoholic fatty liver disease (NAFLD), due to its impact on lipid transport and storage.
Recombinant APOO protein is engineered using heterologous expression systems (e.g., E. coli, mammalian cells) to produce purified, functional APOO for research and therapeutic applications. Its recombinant form enables detailed studies of APOO’s molecular mechanisms, including its role in cellular stress responses and interactions with lipid particles. Recent research also explores APOO’s potential as a biomarker for metabolic syndromes or a target for therapies addressing mitochondrial dysfunction.
Despite progress, APOO’s full physiological significance remains under investigation. Current efforts focus on elucidating its tissue-specific functions, post-translational modifications, and relevance in neurodegenerative conditions. Recombinant APOO tools are critical for advancing these studies, offering insights into mitochondrial biology and disease pathways.
×
